Amgen Inc. (NASDAQ:AMGN):
Second Phase 3 Study Shows KYPROLISÂ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma.
The company is trading down from yesterday’s close of $173.32.
The company recently announced a dividend paid on Thursday June 8th, 2017. The dividend payment was $1.150 per share for the quarter or $4.60 annualized. This dividend represents a yield of $2.68. The ex-dividend date was Monday the 15th of May 2017.
Amgen Inc., launched on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Business’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience..
Shares of the company are trading at $173.27 a bit higher than the 50 day moving average which is $162.22 and which is marginally over the 200 day moving average of $162.64. The 50 day moving average was up $11.05 whereas the 200 day average was up by +6.54%.
Amgen Inc.’s P/E ratio is 16.46 and the market value is 127.42B. In the last earnings report the EPS was $10.53 and is projected to be $12.43 for the current year with 735,399,000 shares outstanding. Next quarter’s EPS is forecasted to be $3.12 with next year’s EPS projected to be $12.76.
Traders are a little more bearish on shares of the company considering the increase in short interest. The stock saw a rise in short interest from June 15, 2017 to May 31, 2017 of 11.16%. Short shares increased from 8,108,203 to 9,013,072 over that timeframe. The short-interest ratio increased to 2.6 and the percentage of shorted shares was 0.01% on May 31.
Several investment analysts have issued ratings on AMGN of late. On July 11 Morgan Stanley left the company rating at “Overweight” but lowered the price target from $198.00 to $189.00. On December 13, 2016 Oppenheimer began coverage of AMGN with an initial rating of “Outperform”.
On November 8 analysts at Mizuho starting coverage on the stock setting a rating of “Buy”. September 28 investment analysts at Citigroup made no change to the stock rating of “Neutral” but lowered the price expectation to $172.00 from $198.00.
Equity analyst Gabelli & Co. started coverage by announcing an initial rating of “Hold”. Bernstein initiated coverage on the stock giving it an initial rating of “Market Perform”.